Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2021

View Archived Issues

Predicting phase separation

Microbiome fungi counter systemic infections

SorLA identified as a target in anti-HER2-resistant HER2-positive breast cancer

Initiation of phase II study assessing IRX-2 plus pembrolizumab and chemotherapy in TNBC

European Commission approves additional indication for clopidogrel

NSC-765690 and NSC-765599 show antitumor activity against NCI60 human tumor cell lines

Teon Therapeutics patents new adenosine A2A receptor antagonists

Idorsia Pharmaceuticals discloses new antibacterials

Shouyao Holdings (Beijing) identifies new Ret inhibitors

OncoArendi Therapeutics discovers AMCase and CHIT1 inhibitors

U.S. researchers divulge new immunotherapeutic constructs for cancer

Phase III study of napabucasin in metastatic colorectal cancer misses primary endpoints

Trefoil initiates phase II study of TTHX-1114 for Fuchs endothelial corneal dystrophy

PaxMedica reports phase II data on PAX-101 for autism spectrum disorder

Glycosylation study casts new light on health and disease

Durvalumab data presented from SAFIR02-BREAST IMMUNO trial

NeuroRx reports preliminary phase IIb/III trial data on Zyesami in COVID-19 respiratory failure

Sotio ends phase I trial of ONCOS-102 with DCVAC/PCa in prostate cancer

Basilea reports cohort 1 data from phase II study of derazantinib in intrahepatic cholangiocarcinoma

VDA-1102 studied in new phase II trial for early forms of cutaneous T-cell lymphoma

AC Immune begins first-in-human study of ACI-12589 as diagnostic for Parkinson's disease

FDA approves Libtayo for advanced basal cell carcinoma

Agenus reports additional confirmed objective clinical responses from phase I/II trial of AGEN-1181

FDA grants EUA for etesevimab and bamlanivimab for mild to moderate COVID-19

Heat Biologics reports interim phase II data on HS-110 with nivolumab in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...